Sherilyn Gross

last updated 1/24/2018

Sherilyn A. Gross

Senior Health Scientist at ChemRisk Inc

Location:
101 2nd Street, Suite 700, San Francisco, California, United States
Company:
ChemRisk Inc
HQ Phone:
(415) 896-2400

General Information

Experience

Research Professor - Colorado University

Principle Investigator On Behalf - University of Colorado for the Shanghai Health Study

Recent News  

ChemRisk - Consultant Profile - Scientific Consultants

Sherilyn A. Gross, LN, Ph.D., CCRP; Senior Health Scientist
Dr. Sherilyn Gross is a toxicologist with 15 years of experience conducting studies evaluating human health risks following exposure to benzene. Since joining the ChemRisk team in February 2010, Dr. Gross has used her expertise to provide technical and litigation support in assessing health effects associated occupational exposure to benzene. Her career goal at ChemRisk is to serve as the technical lead for all projects relating to benzene. Prior to joining ChemRisk, Dr. Gross was an Assistant Research Professor and the University of Colorado Health Sciences Center where she served as the Principle Investigator on behalf of the University of Colorado for the Shanghai Health Study (SHS). Her role in SHS was to evaluate the risk associated with development of hematopoietic and lymphoid diseases in a hospital based case control study in cases with the potential for occupational exposure to benzene and other toxic agent. Dr. Gross also served as the Assistant Director for Clinical Research Coordination and Compliance where her responsibility was to assure compliance of SHS and operations with the US Office of Human Research Protection and the International Conference on Harmonization for research study with human subjects. This required the implementation and monitoring of appropriate procedures for recruitment and study participation for subjects diagnosed with aplastic anemia, myelodysplastic syndrome, acute myelogenous leukemia and non-Hodgkin's lymphoma. Dr. Gross performed her post-graduate work at the University of Colorado School of Medicine, Department of Medical Oncology, Bone Marrow Transplant Program (BMTP). Dr. Gross collaborated with physicians in the BMTP at the University Hospital to develop research projects in translational medicine. Specifically, she evaluated the therapeutic potential for ex vivo expansion of hematopoietic cell subpopulations as treatment for graft-versus-host disease, diseases of the hematopoietic system and cellular support for chemotherapeutic regimens. Dr. Gross's graduate laboratory research principally addressed the molecular mechanism of action of benzene metabolites in human bone marrow cells. She designed and conducted toxicological studies and developed new and innovative cellular and molecular techniques to explore the mechanism(s) for benzene-induced alterations in differentiation and proliferation of human stem and progenitor cells.

Read More
http://www.cardnochemrisk.com/index.php?option=com_content&view=article&id=787&Itemid=10

Sherilyn Gross, LN, PhD, CCRP; Senior Health Scientist
Dr. Sherilyn Gross is a toxicologist with 15 years of experience conducting studies evaluating human health risks following exposure to benzene. Since joining the Cardno ChemRisk team in February 2010, Dr. Gross has used her expertise to provide technical and litigation support in assessing health effects associated occupational exposure to benzene. Her career goal at Cardno ChemRisk is to serve as the technical lead for all projects relating to benzene. Prior to joining Cardno ChemRisk, Dr. Gross was an Assistant Research Professor and the University of Colorado Health Sciences Center where she served as the Principle Investigator on behalf of the University of Colorado for the Shanghai Health Study (SHS). Her role in SHS was to evaluate the risk associated with development of hematopoietic and lymphoid diseases in a hospital based case control study in cases with the potential for occupational exposure to benzene and other toxic agent. Dr. Gross also served as the Assistant Director for Clinical Research Coordination and Compliance where her responsibility was to assure compliance of SHS and operations with the US Office of Human Research Protection and the International Conference on Harmonization for research study with human subjects. This required the implementation and monitoring of appropriate procedures for recruitment and study participation for subjects diagnosed with aplastic anemia, myelodysplastic syndrome, acute myelogenous leukemia and non-Hodgkin's lymphoma. Dr. Gross performed her post-graduate work at the University of Colorado School of Medicine, Department of Medical Oncology, Bone Marrow Transplant Program (BMTP). Dr. Gross collaborated with physicians in the BMTP at the University Hospital to develop research projects in translational medicine. Specifically, she evaluated the therapeutic potential for ex vivo expansion of hematopoietic cell subpopulations as treatment for graft-versus-host disease, diseases of the hematopoietic system and cellular support for chemotherapeutic regimens. Dr. Gross's graduate laboratory research principally addressed the molecular mechanism of action of benzene metabolites in human bone marrow cells. She designed and conducted toxicological studies and developed new and innovative cellular and molecular techniques to explore the mechanism(s) for benzene-induced alterations in differentiation and proliferation of human stem and progenitor cells.

Read More

Browse ZoomInfo’s Directories